Treats major depressive disorder (MDD). ANDA 206923, held by Accord Hlthcare. Trazodone Hydrochloride.
As of Nov 16, 2026, ANDA 206923 (Trazodone Hydrochloride), held by Accord Hlthcare, was first approved by FDA on Sep 8, 2017, with 3 approved supplements and 0 published complete response letters.
Trazodone hydrochloride tablets are indicated for the treatment of major depressive disorder (MDD) in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 8, 2017 | Original application | Approved | None posted |
| Trazodone Hydrochloride50MG · tablet;oral | Trazodone Hydrochloride | Rx |
| Trazodone Hydrochloride100MG · tablet;oral | Trazodone Hydrochloride | Rx |
| Trazodone Hydrochloride150MG · tablet;oral | Trazodone Hydrochloride | Rx |
| Trazodone Hydrochloride300MG · tablet;oral | Trazodone Hydrochloride | Rx |
| Jun 24, 2025 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jun 16, 2025 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jun 16, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| Sep 8, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters